Topical atorvastatin 1% for prevention of skin toxicity in patients receiving radiation therapy for breast cancer: a randomized, double-blind, placebo-controlled trial
Background and purpose
The purpose of this randomized, placebo-controlled, double-blind study was to investigate the preventive effect of topical administration of atorvastatin (ATV) on the acute radiation-induced skin toxicity in patients with breast cancer.
Patients and methods
Seventy breast cancer patients were randomly assigned to use topical ATV 1% or placebo gels during radiotherapy twice daily. Radiation-induced dermatitis was classified according to the radiation therapy oncology group (RTOG) criteria, as well as pain and itching were scored according to VAS (visual analogue scale) for 6 weeks of treatment.
Topical administration of ATV gel during radiotherapy reduced significantly radiation-induced breast swelling, itching, and pain in breast cancer patients by factors of 1.8, 1.7, and 1.5, respectively. ATV reduced the redness caused by radiotherapy in patients as compared with placebo; however, this difference was statistically not significant.
ATV was able to reduce significantly itching, breast edema, and pain in patients during radiotherapy.
KeywordsAtorvastatin Skin toxicity Radiotherapy Radioprotective
This research was the subject of a thesis of Zahra Ghashghaei as a Pharm D. student of Mazandaran University of Medical Science.
This study was supported by a grant from Mazandaran University of Medical Science, Sari, Iran.
Compliance with ethical standards
Conflict of interest statement
The authors declare that they had no conflicts of interest.
- 3.Overgaard M, Hansen PS, Overgaard J, Rose C, Andersson M, Bach F, Kjaer M, Gadeberg CC, Mouridsen HT, Jensen MB, Zedeler K (1997) Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish breast Cancer cooperative group 82b trial. N Engl J Med 337(14):949–955. https://doi.org/10.1056/NEJM199710023371401 CrossRefPubMedGoogle Scholar
- 6.Chan RJ, Keller J, Cheuk R, Blades R, Tripcony L, Keogh S (2012) A double-blind randomised controlled trial of a natural oil-based emulsion (Moogoo Udder Cream®) containing allantoin versus aqueous cream for managing radiation-induced skin reactions in patients with cancer. Radiat Oncol 7:121. https://doi.org/10.1186/1748-717X-7-121 CrossRefPubMedPubMedCentralGoogle Scholar
- 8.Kang HC, Ahn SD, Choi DH, Kang MK, Chung WK, Wu HG (2014) The safety and efficacy of EGF-based cream for the prevention of radiotherapy-induced skin injury: results from a multicenter observational study. Radiat Oncol J 32(3):156–162. https://doi.org/10.3857/roj.2014.32.3.156 CrossRefPubMedPubMedCentralGoogle Scholar
- 17.Asai J, Takenaka H, Hirakawa S, Sakabe J, Hagura A, Kishimoto S, Maruyama K, Kajiya K, Kinoshita S, Tokura Y, Katoh N (2012) Topical simvastatin accelerates wound healing in diabetes by enhancing angiogenesis and lymphangiogenesis. Am J Pathol 181(6):2217–2224. https://doi.org/10.1016/j.ajpath.2012.08.023 CrossRefPubMedGoogle Scholar
- 22.Chang CZ, Wu SC, Lin CL, Hwang SL, Howng SL, Kwan AL (2010) Atorvastatin preconditioning attenuates the production of endothelin-1 and prevents experimental vasospasm in rats. Acta Neurochir 152(8):1399–1406; discussion 1405-1396. https://doi.org/10.1007/s00701-010-0652-3 CrossRefPubMedGoogle Scholar
- 23.Pathak NN, Balaganur V, Lingaraju MC, More AS, Kant V, Kumar D, Kumar D, Tandan SK (2013) Antihyperalgesic and anti-inflammatory effects of atorvastatin in chronic constriction injury-induced neuropathic pain in rats. Inflammation 36(6):1468–1478. https://doi.org/10.1007/s10753-013-9688-x CrossRefPubMedGoogle Scholar
- 27.Jacobson G, Bhatia S, Smith BJ, Button AM, Bodeker K, Buatti J (2013) Randomized trial of pentoxifylline and vitamin E vs standard follow-up after breast irradiation to prevent breast fibrosis, evaluated by tissue compliance meter. Int J Radiat Oncol Biol Phys 85(3):604–608. https://doi.org/10.1016/j.ijrobp.2012.06.042 CrossRefPubMedGoogle Scholar
- 31.Harsolia A, Kestin L, Grills I, Wallace M, Jolly S, Jones C, Lala M, Martinez A, Schell S, Vicini FA (2007) Intensity-modulated radiotherapy results in significant decrease in clinical toxicities compared with conventional wedge-based breast radiotherapy. Int J Radiat Oncol Biol Phys 68(5):1375–1380. https://doi.org/10.1016/j.ijrobp.2007.02.044 CrossRefPubMedGoogle Scholar
- 33.Freedman GM, Li T, Nicolaou N, Chen Y, Ma CC, Anderson PR (2009) Breast intensity-modulated radiation therapy reduces time spent with acute dermatitis for women of all breast sizes during radiation. Int J Radiat Oncol Biol Phys 74(3):689–694. https://doi.org/10.1016/j.ijrobp.2008.08.071 CrossRefPubMedPubMedCentralGoogle Scholar
- 34.Zygogianni A, Kouloulias V, Antypas C, Armpilia C, Kyrgias G, Kouvaris J (2014) The impact of intermediate time between chemotherapy and hypofractionated radiotherapy to the radiation induced skin toxicity for breast adjuvant treatment. Breast J 20(1):74–78. https://doi.org/10.1111/tbj.12206 CrossRefPubMedGoogle Scholar
- 35.James ML, Lehman M, Hider PN, Jeffery M, Francis DP, Hickey BE (2008) Fraction size in radiation treatment for breast conservation in early breast cancer. Cochrane Database Syst Rev (3): CD003860. https://doi.org/10.1002/14651858.CD003860.pub2
- 36.Harper JL, Franklin LE, Jenrette JM, Aguero EG (2004) Skin toxicity during breast irradiation: pathophysiology and management. South Med J 97(10):989–993. https://doi.org/10.1097/01.SMJ.0000140866.97278.87 CrossRefPubMedGoogle Scholar
- 37.Hosseinimehr SJ, Izakmehri M, Ghasemi A (2015) In vitro protective effect of atorvastatin against ionizing radiation induced genotoxicity in human lymphocytes. Cell Mol Biol (Noisy-le-grand) 61(1):68–71Google Scholar
- 38.Hamzeh M, Talebpour Amiri F, Karimpour Malekshah A, Yaghubi Beklar S, Hosseinimehr J (2017) Protective effect of atorvastatin against cardiotoxicity and hematotoxicity induced by cyclophosphamide in rat. J Mazand Univ Med Sci 27(151):1–11Google Scholar
- 41.Barnett GC, Wilkinson JS, Moody AM, Wilson CB, Twyman N, Wishart GC, Burnet NG, Coles CE (2011) The Cambridge Breast Intensity-modulated Radiotherapy Trial: patient- and treatment-related factors that influence late toxicity. Clin Oncol (R Coll Radiol) 23(10):662–673. https://doi.org/10.1016/j.clon.2011.04.011 CrossRefGoogle Scholar
- 44.Bani HA, Fasching PA, Lux MM, Rauh C, Willner M, Eder I, Loehberg C, Schrauder M, Beckmann MW, Bani MR (2007) Lymphedema in breast cancer survivors: assessment and information provision in a specialized breast unit. Patient Educ Couns 66(3):311–318. https://doi.org/10.1016/j.pec.2007.01.004 CrossRefPubMedGoogle Scholar
- 47.Kulkarni NM, Muley MM, Jaji MS, Vijaykanth G, Raghul J, Reddy NK, Vishwakarma SL, Rajesh NB, Mookkan J, Krishnan UM, Narayanan S (2015) Topical atorvastatin ameliorates 12-O-tetradecanoylphorbol-13-acetate induced skin inflammation by reducing cutaneous cytokine levels and NF-kappaB activation. Arch Pharm Res 38(6):1238–1247. https://doi.org/10.1007/s12272-014-0496-0 CrossRefPubMedGoogle Scholar
- 50.Napimoga MH, Souza GR, Cunha TM, Ferrari LF, Clemente-Napimoga JT, Parada CA, Verri WA Jr, Cunha FQ, Ferreira SH (2008) 15d-prostaglandin J2 inhibits inflammatory hypernociception: involvement of peripheral opioid receptor. J Pharmacol Exp Ther 324(1):313–321. https://doi.org/10.1124/jpet.107.126045 CrossRefPubMedGoogle Scholar